STOCK TITAN

Orchestra BioMed Holdings (OBIO) Stock Price, News & Analysis

OBIO NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
45 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
+19.9% close of August 18, 2026
1-year change
+73.4% closing prices, November 13, 2025 to November 13, 2026
1-month change
+26.7% closing prices, October 13, 2026 to November 13, 2026

Company Description

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical innovation company that focuses on accelerating high-impact technologies to patients through strategic collaborations and risk-reward sharing partnerships with global medical device companies. According to the company’s disclosures, its partnership-enabled business model centers on forging long-term, strategically aligned relationships to drive development and commercialization of its product candidates.

The company’s lead programs are two flagship product candidates that target major cardiovascular conditions. Atrioventricular Interval Modulation (AVIM) Therapy, also referred to as BackBeat Cardiac Neuromodulation Therapy (CNT), is described as a bioelectronic treatment for hypertension, which the company characterizes as the leading risk factor for death worldwide. AVIM Therapy is designed to be delivered as a firmware upgrade to a standard dual-chamber pacemaker and is intended to achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease who are indicated for a pacemaker. The therapy has been evaluated in pilot studies and is being advanced in the BACKBEAT global pivotal study for patients with systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker.

Orchestra BioMed reports that AVIM Therapy has received FDA Breakthrough Device Designation for the treatment of uncontrolled hypertension in patients with increased cardiovascular risk, including an estimated 7.7 million patients in the U.S. with uncontrolled hypertension despite medical therapy. The company also notes a strategic collaboration with Medtronic, described as one of the largest medical device companies in the world, for development and commercialization of AVIM Therapy in pacemaker-indicated patients. An amendment to this collaboration provides a framework for potential future integration of AVIM Therapy into dual-chamber leadless pacemakers.

The company’s second flagship program is the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), a drug delivery angioplasty balloon system designed to deliver a proprietary extended-release formulation of sirolimus, known as SirolimusEFR. Virtue SAB uses a non-coated microporous AngioInfusion Balloon to protect the drug in transit and deliver a large liquid dose directly to the vessel wall. Company materials describe Virtue SAB as a highly differentiated, first-of-its-kind system intended for the treatment of atherosclerotic artery disease, which it characterizes as the leading cause of mortality worldwide.

Virtue SAB has been studied in preclinical and clinical settings. Published preclinical work cited by the company indicates that SirolimusEFR delivered by Virtue SAB can achieve sustained tissue levels above a known therapeutic concentration for inhibiting restenosis through a critical healing period of approximately 30 days. In the SABRE clinical study in Europe, Virtue SAB demonstrated positive three-year data in coronary in-stent restenosis (ISR) in a multi-center, prospective, independent core lab-adjudicated study. Orchestra BioMed states that Virtue SAB has FDA Breakthrough Device Designation for the treatment of coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease.

Both AVIM Therapy and Virtue SAB are described by the company as being in pivotal clinical trials for their lead indications, which it characterizes as multi-billion-dollar annual global market opportunities. The Virtue Trial, a U.S. investigational device exemption (IDE) pivotal trial, is a randomized head-to-head coronary study comparing Virtue SAB to the AGENT paclitaxel-coated balloon for treatment of coronary ISR. The trial is designed to support regulatory approval in the United States and is expected to enroll hundreds of patients across multiple centers.

Orchestra BioMed emphasizes a partnership-driven approach to advancing these programs. The company has a strategic collaboration with Medtronic for AVIM Therapy and has entered into a right of first refusal agreement with Terumo Corporation and Terumo Medical Corporation related to potential future transactions involving Virtue SAB for coronary artery disease. Under this arrangement, Terumo has a right of first refusal on certain Virtue SAB coronary transactions, while Orchestra BioMed retains development and distribution rights across all indications. The company has also entered into a revenue participation right purchase and sale agreement with Ligand Pharmaceuticals Incorporated, under which Ligand receives tiered revenue participation tied to future revenues from AVIM Therapy and Virtue SAB in specified fields.

In addition to its core programs, Orchestra BioMed has engaged in strategic investments and capital transactions to support its clinical and development activities. These include public equity offerings, private placements of common stock, issuance of pre-funded warrants, and preferred stock financings. The company has also entered into a secured subordinated convertible loan agreement with Medtronic that can convert into a share of revenue associated with AVIM Therapy if specified regulatory milestones are achieved.

Orchestra BioMed describes itself as an emerging growth company and a biomedical innovation platform that seeks to align with market-leading medical device partners to advance device-based therapies for cardiovascular disease. Its disclosures highlight hypertension and atherosclerotic artery disease as central disease areas, with AVIM Therapy and Virtue SAB positioned as investigational approaches that aim to address unmet needs in hypertensive heart disease, coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease.

Business model and partnerships

The company’s stated business model is based on risk-reward sharing partnerships and strategic collaborations. It reports that this model is intended to combine its internal development capabilities with the scale and commercial infrastructure of larger medical device companies. Examples include the collaboration with Medtronic for AVIM Therapy and agreements with Terumo related to Virtue SAB. The company has also structured revenue participation and financing arrangements, such as its agreement with Ligand, that are tied to future product revenues.

Clinical development focus

Orchestra BioMed’s disclosures emphasize pivotal-stage clinical development. The BACKBEAT global pivotal study is designed to evaluate AVIM Therapy in patients with uncontrolled hypertension who are indicated for a dual-chamber pacemaker. The Virtue Trial is described as a U.S. IDE pivotal trial comparing Virtue SAB to a commercially available paclitaxel-coated balloon in coronary ISR. These trials are intended to generate data to support regulatory submissions and potential commercialization pathways in collaboration with partners.

Capital markets and regulatory status

Orchestra BioMed’s securities filings indicate that the company has conducted underwritten public offerings of common stock and pre-funded warrants, as well as concurrent private placements with institutional partners. It has also entered into agreements that provide tiered revenue interests and convertible debt tied to the performance and commercialization of its flagship programs. The company identifies itself as an emerging growth company under applicable U.S. securities regulations and files current reports on Form 8-K to disclose material agreements, financings and investor presentations.

Stock Performance

$7.27
+0.32%
+0.02
After hoursChange vs the $7.25 closeLast updated: November 13, 2026 at 19:19
+73.4%
Performance 1 year
$572.4M

Orchestra BioMed Holdings (OBIO) closed at $7.25 on November 13, 2026. Over the past 12 months, the price has gained 73.4%.

See what a $1,000 investment in OBIO would be worth today

Average down calculator for OBIO

OBIO Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Buyers
90-Day Summary
1,238,000
Shares Bought
45,000
Shares Sold
9
Transactions
Most Recent Transaction
RTW INVESTMENTS, LP (10% Owner) bought 1,200,000 shares held indirectly @ $5.00 on November 9, 2026

Insider buying activity at Orchestra BioMed Holdings over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Orchestra BioMed Holdings generated $33.5M in revenue in FY2025, retaining a 99.4% gross margin, operating income reached -$51.8M, and net income was -$52.7M. Diluted earnings per share stood at -$1.11. The company generated -$49.0M in operating cash flow. The current ratio was 6.45, measuring current assets divided by current liabilities.

$33.5M
Revenue (FY2025)
-$52.7M
Net Income (FY2025)
-$49.0M
Operating Cash Flow

Upcoming Events

DEC
05
December 5, 2026 Financial

Underwriter option expiration

30-day option to underwriters to purchase up to 15% additional shares at the public offering price; expires 2026-12-05.
DEC
09
December 9, 2026 Financial

Underwriter option expiry

End of 30-day underwriter option to purchase up to 2,250,000 additional shares following offering closing on Nov 9, 2026.
YEAR
2027
2027 Clinical

HRS 2027 presentation

Submit BACKBEAT primary endpoint results for presentation consideration at HRS 2027; pivotal results to be presented at HRS if accepted.
YEAR
2027
2027 Clinical

Virtue enrollment completion

Virtue trial targets enrollment completion by the end of 2027; milestone could affect development timeline and future results.
Q2
2027
Q2 2027 Clinical

Late-breaking submission

Orchestra BioMed and Medtronic to submit BACKBEAT primary results for late-breaking presentation consideration between Apr–Jun 2027.
Q2
2027
Q2 2027 Clinical

Primary endpoint presentation

Primary endpoint data presentation for BACKBEAT pivotal trial (AVIM Therapy); results planned for Q2 2027.
Q2
2027
Q2 2027 Clinical

Late-breaking data presentation

Aims for late-breaking BACKBEAT data presentation in Q2 2027; likely conference session, webcast or details to be announced.
YEAR
2027
2027 Clinical

Enrollment completion planned

Completion of patient enrollment for pivotal IDE Virtue SAB trial
H2
2027
H2 2027 Clinical

BACKBEAT enrollment completion

Expected completion of BACKBEAT study enrollment
H2
2027
H2 2027 Clinical

Virtue Trial enrollment milestone

Anticipated substantial enrollment in Virtue trial
SEP
01
September 1, 2030 Corporate

Options final vesting

Final vesting of 133,000 new-hire stock options granted Sept 1, 2026; four-year vesting schedule concludes on 2030-09-01.

Orchestra BioMed Holdings has 11 upcoming scheduled events. The next event, "Underwriter option expiration", is scheduled for December 5, 2026 (in 19 days). 2 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the OBIO stock price.

Short Interest History

Last 12 Months

Short interest in Orchestra BioMed Holdings (OBIO) currently stands at 2.7 million shares, up 7.0% from the previous reporting period, representing 4.6% of the float. Since November 2025, short interest has increased by 252.9%.

Days to Cover History

Last 12 Months

Days to cover for Orchestra BioMed Holdings (OBIO) currently stands at 7.0 days, down 27.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 253%. Across the settlements charted above, it has ranged from 2.0 to 13.4 days.

OBIO Company Profile & Sector Positioning

Orchestra BioMed Holdings (OBIO) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing OBIO often look at related companies in the same sector, including Eupraxia Pharmaceuticals Inc. (EPRX), Aclaris Therapeutics, Inc. (ACRS), Capricor Therapeutics Inc (CAPR), Valneva SE (VALN), and Olema Oncology, Inc. (OLMA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate OBIO's relative position within its industry.

Frequently Asked Questions

The current stock price of Orchestra BioMed Holdings (OBIO) is $7.27 in after-hours trading as of November 13, 2026.

The market cap of Orchestra BioMed Holdings (OBIO) is approximately $572.4M. Learn more about what market capitalization means .

The FY2025 revenue of Orchestra BioMed Holdings (OBIO) is $33.5M, from its most recent completed fiscal year.

The FY2025 net income of Orchestra BioMed Holdings (OBIO) is -$52.7M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Orchestra BioMed Holdings (OBIO) is -$1.11 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Orchestra BioMed Holdings (OBIO) is -$49.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The gross profit margin of Orchestra BioMed Holdings (OBIO) is 99.4% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Orchestra BioMed Holdings (OBIO), current assets divided by current liabilities, was 6.45 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Orchestra BioMed Holdings (OBIO) is $33.3M for FY2025, its most recent completed fiscal year.

The operating income of Orchestra BioMed Holdings (OBIO) is -$51.8M for FY2025, its most recent completed fiscal year. Learn about operating income.